Global Therapeutic Drug Monitoring Market Growth (Status and Outlook) 2025-2031

Global Therapeutic Drug Monitoring Market Growth (Status and Outlook) 2025-2031

The global Therapeutic Drug Monitoring market size is predicted to grow from US$ 2098 million in 2025 to US$ 3545 million in 2031; it is expected to grow at a CAGR of 9.1% from 2025 to 2031.

Therapeutic drug monitoring (TDM), a clinical laboratory technology that measures drug concentrations to regulate drug dosage, has become an important treatment aid in both inpatient and ambulatory care. TDM laboratory methods, including immunoassay (EIA, FIA, and RIA) and chromatographic techniques, used to assay blood, urine, and saliva samples of patients taking therapeutic drugs; TDM is also useful in identifying abused drugs. Therapeutic drug monitoring (TDM) is the clinical practice of measuring specific drugs at designated intervals to maintain a constant concentration in a patient's bloodstream, thereby optimizing individual dosage regimens. It is unnecessary to employ TDM for the majority of medications, and it is used mainly for monitoring drugs with narrow therapeutic ranges, drugs with marked pharmacokinetic variability, medications for which target concentrations are difficult to monitor, and drugs known to cause therapeutic and adverse effects.

The Therapeutic Drug Monitoring (TDM) market is growing due to an increasing focus on personalized medicine, which tailors treatments to the individual characteristics of each patient. TDM enables clinicians to optimize drug dosages for better efficacy and reduced toxicity, particularly important for drugs with narrow therapeutic windows, such as immunosuppressants, anti-epileptics, and certain antibiotics. As the incidence of chronic diseases rises globally, there is greater demand for precise dosing in treatments, which supports TDM's expanding role. Additionally, technological advancements in laboratory automation and assay sensitivity are making TDM more accessible and accurate, further driving market growth.

A significant challenge in the TDM market is the high cost of testing and the need for specialized equipment and expertise, which can limit its accessibility, especially in lower-income regions. TDM requires sophisticated instruments and skilled personnel to interpret results accurately, leading to a barrier for healthcare facilities without sufficient resources. Furthermore, in some cases, there is a lack of standardized protocols for monitoring certain drugs, creating inconsistencies in practices across healthcare systems. These factors may hinder the widespread adoption of TDM, especially in resource-constrained settings.

Global therapeutic drug monitoring key players include Roche, Danaher and Abbott.The top 5 accounts for 60% of the revenue. By region, North America had the highest share of income, reaching 45%.In terms of product, blood test is the largest segment, with a share over 70%. And in terms of application, the largest application is hospital labs, followed by independent clinical laboratories.

LPI (LP Information)' newest research report, the “Therapeutic Drug Monitoring Industry Forecast” looks at past sales and reviews total world Therapeutic Drug Monitoring sales in 2024, providing a comprehensive analysis by region and market sector of projected Therapeutic Drug Monitoring sales for 2025 through 2031. With Therapeutic Drug Monitoring sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Therapeutic Drug Monitoring industry.

This Insight Report provides a comprehensive analysis of the global Therapeutic Drug Monitoring landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Therapeutic Drug Monitoring portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Therapeutic Drug Monitoring market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Therapeutic Drug Monitoring and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Therapeutic Drug Monitoring.

This report presents a comprehensive overview, market shares, and growth opportunities of Therapeutic Drug Monitoring market by product type, application, key players and key regions and countries.

Segmentation by Type:
Blood Test
Urine Test
Saliva Test

Segmentation by Application:
Hospital Labs
Independent Clinical Laboratories
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Danaher
Abbott
Thermo Fisher Scientific
Siemens Healthineers
Bio-Rad Laboratories
bioMerieux
Bühlmann Laboratories
Randox Laboratories
Sekisui Medical
DAT Diagnostic
Chromai